TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06388707: A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

Sponsor: NaviFUS Corporation · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$725,560

Rescue Site Savings

+$494,700

Unlock Full NCT06388707 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06388707 Rescue Dossier →